FDA Denies Approval for Hemispherx’s Fatigue Drug

Hemispherx Biopharma Inc said U.S. health regulators did not approve its experimental drug Ampligen for the treatment of chronic fatigue syndrome, sending its shares down 45 percent in after-hours trade.
Forbes